The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/study/NCT05776472




Registration number
Help: Registration number
NCT05776472
Ethics application status
Help: Ethics application status
Date submitted
Help: Date submitted
20/02/2023
Date registered
Help: Date registered
20/03/2023
Date last updated
Help: Date last updated
3/09/2026

Titles & IDs
Public title
A Real World Effectiveness Study of Pegcetacoplan in Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH)
Scientific title
A Single Arm, Long-term, Multicentre Observational Study to Evaluate Effectiveness of Pegcetacoplan Under Real World Conditions in Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH)
Additional trial identifiers [1] 0 0
Sobi.PEGCET-304
Universal Trial Number (UTN)
Trial acronym
COMPLETE
Related trial records

Health condition
Health condition(s) studied:
Paroxysmal Nocturnal Hemoglobinuria 0 0
Condition category
Condition code
Blood 0 0 0 0
Haematological diseases

Intervention/exposure
Study type
Observational
Patient registry
Target follow-up duration
Target follow-up type
Description of the intervention or exposure
Treatment: Drugs - Pegcetacoplan

Treatment: Drugs: Pegcetacoplan
Pegcetacoplan will be prescribed according to the label in patients with PNH.

Intervention code [1] 0 0
Treatment: Drugs
Description of the comparator or control
Control group

Outcomes
Primary outcome [1] 0 0
Change in observed hemoglobin level from initiation of treatment with pegcetacoplan to 6 months
Timepoint [1] 0 0
6 months
Secondary outcome [1] 0 0
Change of LDH values from initiation of pegcetacoplan treatment to 6 months
Timepoint [1] 0 0
6 months
Secondary outcome [2] 0 0
Change in Absolute Reticulocyte Count (ARC) from initiation of pegcetacoplan treatment to 6 months
Timepoint [2] 0 0
6 months
Secondary outcome [3] 0 0
Change in indirect/ total bilirubin from initiation of pegcetacoplan treatment to 6 months
Timepoint [3] 0 0
6 months
Secondary outcome [4] 0 0
Change in Haptoglobin from initiation of pegcetacoplan treatment to 6 months
Timepoint [4] 0 0
6 months
Secondary outcome [5] 0 0
Change in Ferritin from initiation of pegcetacoplan treatment to 6 months
Timepoint [5] 0 0
6 months
Secondary outcome [6] 0 0
Hemoglobin at initiation of pegcetacoplan treatment and each 6 months until end of follow-up
Timepoint [6] 0 0
6 months
Secondary outcome [7] 0 0
Hemoglobin at initiation of pegcetacoplan treatment and each 6 months until end of follow-up
Timepoint [7] 0 0
12 months
Secondary outcome [8] 0 0
Hemoglobin at initiation of pegcetacoplan treatment and each 6 months until end of follow-up
Timepoint [8] 0 0
18 months
Secondary outcome [9] 0 0
Hemoglobin at initiation of pegcetacoplan treatment and each 6 months until end of follow-up
Timepoint [9] 0 0
24 months
Secondary outcome [10] 0 0
Hemoglobin at initiation of pegcetacoplan treatment and each 6 months until end of follow-up
Timepoint [10] 0 0
30 months
Secondary outcome [11] 0 0
Hemoglobin at initiation of pegcetacoplan treatment and each 6 months until end of follow-up
Timepoint [11] 0 0
36 months
Secondary outcome [12] 0 0
Lactate Dehydrogenase at initiation of pegcetacoplan treatment and each 6 months until end of follow-up
Timepoint [12] 0 0
6 months
Secondary outcome [13] 0 0
Lactate Dehydrogenase at initiation of pegcetacoplan treatment and each 6 months until end of follow-up
Timepoint [13] 0 0
12 months
Secondary outcome [14] 0 0
Lactate Dehydrogenase at initiation of pegcetacoplan treatment and each 6 months until end of follow-up
Timepoint [14] 0 0
18 months
Secondary outcome [15] 0 0
Lactate Dehydrogenase at initiation of pegcetacoplan treatment and each 6 months until end of follow-up
Timepoint [15] 0 0
24 months
Secondary outcome [16] 0 0
Lactate Dehydrogenase at initiation of pegcetacoplan treatment and each 6 months until end of follow-up
Timepoint [16] 0 0
30 months
Secondary outcome [17] 0 0
Lactate Dehydrogenase at initiation of pegcetacoplan treatment and each 6 months until end of follow-up
Timepoint [17] 0 0
36 months
Secondary outcome [18] 0 0
Absolute Reticulocyte Count at initiation of pegcetacoplan treatment and each 6 months until end of follow-up
Timepoint [18] 0 0
6 months
Secondary outcome [19] 0 0
Absolute Reticulocyte Count at initiation of pegcetacoplan treatment and each 6 months until end of follow-up
Timepoint [19] 0 0
12 months
Secondary outcome [20] 0 0
Absolute Reticulocyte Count at initiation of pegcetacoplan treatment and each 6 months until end of follow-up
Timepoint [20] 0 0
18 months
Secondary outcome [21] 0 0
Absolute Reticulocyte Count at initiation of pegcetacoplan treatment and each 6 months until end of follow-up
Timepoint [21] 0 0
24 months
Secondary outcome [22] 0 0
Absolute Reticulocyte Count at initiation of pegcetacoplan treatment and each 6 months until end of follow-up
Timepoint [22] 0 0
30 months
Secondary outcome [23] 0 0
Absolute Reticulocyte Count at initiation of pegcetacoplan treatment and each 6 months until end of follow-up
Timepoint [23] 0 0
36 months
Secondary outcome [24] 0 0
Indirect/ total bilirubin at initiation of pegcetacoplan treatment and each 6 months until end of follow-up
Timepoint [24] 0 0
6 months
Secondary outcome [25] 0 0
Indirect/ total bilirubin at initiation of pegcetacoplan treatment and each 6 months until end of follow-up
Timepoint [25] 0 0
12 months
Secondary outcome [26] 0 0
Indirect/ total bilirubin at initiation of pegcetacoplan treatment and each 6 months until end of follow-up
Timepoint [26] 0 0
18 months
Secondary outcome [27] 0 0
Indirect/ total bilirubin at initiation of pegcetacoplan treatment and each 6 months until end of follow-up
Timepoint [27] 0 0
24 months
Secondary outcome [28] 0 0
Indirect/ total bilirubin at initiation of pegcetacoplan treatment and each 6 months until end of follow-up
Timepoint [28] 0 0
30 months
Secondary outcome [29] 0 0
Indirect/ total bilirubin at initiation of pegcetacoplan treatment and each 6 months until end of follow-up
Timepoint [29] 0 0
36 months
Secondary outcome [30] 0 0
Haptoglobin at initiation of pegcetacoplan treatment and each 6 months until end of follow-up
Timepoint [30] 0 0
6 months
Secondary outcome [31] 0 0
Haptoglobin at initiation of pegcetacoplan treatment and each 6 months until end of follow-up
Timepoint [31] 0 0
12 months
Secondary outcome [32] 0 0
Haptoglobin at initiation of pegcetacoplan treatment and each 6 months until end of follow-up
Timepoint [32] 0 0
18 months
Secondary outcome [33] 0 0
Haptoglobin at initiation of pegcetacoplan treatment and each 6 months until end of follow-up
Timepoint [33] 0 0
24 months
Secondary outcome [34] 0 0
Haptoglobin at initiation of pegcetacoplan treatment and each 6 months until end of follow-up
Timepoint [34] 0 0
30 months
Secondary outcome [35] 0 0
Haptoglobin at initiation of pegcetacoplan treatment and each 6 months until end of follow-up
Timepoint [35] 0 0
36 months
Secondary outcome [36] 0 0
Ferritin at initiation of pegcetacoplan treatment and each 6 months until end of follow-up
Timepoint [36] 0 0
6 months
Secondary outcome [37] 0 0
Ferritin at initiation of pegcetacoplan treatment and each 6 months until end of follow-up
Timepoint [37] 0 0
12 months
Secondary outcome [38] 0 0
Ferritin at initiation of pegcetacoplan treatment and each 6 months until end of follow-up
Timepoint [38] 0 0
18 months
Secondary outcome [39] 0 0
Ferritin at initiation of pegcetacoplan treatment and each 6 months until end of follow-up
Timepoint [39] 0 0
24 months
Secondary outcome [40] 0 0
Ferritin at initiation of pegcetacoplan treatment and each 6 months until end of follow-up
Timepoint [40] 0 0
30 months
Secondary outcome [41] 0 0
Ferritin at initiation of pegcetacoplan treatment and each 6 months until end of follow-up
Timepoint [41] 0 0
36 months
Secondary outcome [42] 0 0
Hemoglobin = 12 g/dL at initiation of pegcetacoplan treatment and each 6 months until end of follow-up
Timepoint [42] 0 0
6 months
Secondary outcome [43] 0 0
Hemoglobin = 12 g/dL at initiation of pegcetacoplan treatment and each 6 months until end of follow-up
Timepoint [43] 0 0
12 months
Secondary outcome [44] 0 0
Hemoglobin = 12 g/dL at initiation of pegcetacoplan treatment and each 6 months until end of follow-up
Timepoint [44] 0 0
18 months
Secondary outcome [45] 0 0
Hemoglobin = 12 g/dL at initiation of pegcetacoplan treatment and each 6 months until end of follow-up
Timepoint [45] 0 0
24 months
Secondary outcome [46] 0 0
Hemoglobin = 12 g/dL at initiation of pegcetacoplan treatment and each 6 months until end of follow-up
Timepoint [46] 0 0
30 months
Secondary outcome [47] 0 0
Hemoglobin = 12 g/dL at initiation of pegcetacoplan treatment and each 6 months until end of follow-up
Timepoint [47] 0 0
36 months
Secondary outcome [48] 0 0
Increase in hemoglobin levels of = 2 g/dL at initiation of pegcetacoplan treatment and each 6 months until end of follow-up
Timepoint [48] 0 0
6 months
Secondary outcome [49] 0 0
Increase in hemoglobin levels of = 2 g/dL at initiation of pegcetacoplan treatment and each 6 months until end of follow-up
Timepoint [49] 0 0
12 months
Secondary outcome [50] 0 0
Increase in hemoglobin levels of = 2 g/dL at initiation of pegcetacoplan treatment and each 6 months until end of follow-up
Timepoint [50] 0 0
18 months
Secondary outcome [51] 0 0
Increase in hemoglobin levels of = 2 g/dL at initiation of pegcetacoplan treatment and each 6 months until end of follow-up
Timepoint [51] 0 0
24 months
Secondary outcome [52] 0 0
Increase in hemoglobin levels of = 2 g/dL at initiation of pegcetacoplan treatment and each 6 months until end of follow-up
Timepoint [52] 0 0
30 months
Secondary outcome [53] 0 0
Increase in hemoglobin levels of = 2 g/dL at initiation of pegcetacoplan treatment and each 6 months until end of follow-up
Timepoint [53] 0 0
36 months
Secondary outcome [54] 0 0
Hemolytic event requiring additional intervention at initiation of pegcetacoplan treatment and each 6 months until end of follow-up
Timepoint [54] 0 0
6 months
Secondary outcome [55] 0 0
Hemolytic event requiring additional intervention at initiation of pegcetacoplan treatment and each 6 months until end of follow-up
Timepoint [55] 0 0
12 months
Secondary outcome [56] 0 0
Hemolytic event requiring additional intervention at initiation of pegcetacoplan treatment and each 6 months until end of follow-up
Timepoint [56] 0 0
18 months
Secondary outcome [57] 0 0
Hemolytic event requiring additional intervention at initiation of pegcetacoplan treatment and each 6 months until end of follow-up
Timepoint [57] 0 0
24 months
Secondary outcome [58] 0 0
Hemolytic event requiring additional intervention at initiation of pegcetacoplan treatment and each 6 months until end of follow-up
Timepoint [58] 0 0
30 months
Secondary outcome [59] 0 0
Hemolytic event requiring additional intervention at initiation of pegcetacoplan treatment and each 6 months until end of follow-up
Timepoint [59] 0 0
36 months
Secondary outcome [60] 0 0
Annualized number of red blood cell (RBC) transfusions during pegcetacoplan treatment until end of follow-up compared to the 12 month period before pegcetacoplan treatment
Timepoint [60] 0 0
12 months
Secondary outcome [61] 0 0
Annualized number of red blood cell (RBC) units during pegcetacoplan treatment until end of follow-up compared to the 12 month period before pegcetacoplan treatment
Timepoint [61] 0 0
12 months
Secondary outcome [62] 0 0
Fatigue at initiation of treatment with pegcetacoplan and every 6 months until end of follow-up
Timepoint [62] 0 0
6 months
Secondary outcome [63] 0 0
Fatigue at initiation of treatment with pegcetacoplan and every 6 months until end of follow-up
Timepoint [63] 0 0
12 months
Secondary outcome [64] 0 0
Fatigue at initiation of treatment with pegcetacoplan and every 6 months until end of follow-up
Timepoint [64] 0 0
18 months
Secondary outcome [65] 0 0
Fatigue at initiation of treatment with pegcetacoplan and every 6 months until end of follow-up
Timepoint [65] 0 0
24 months
Secondary outcome [66] 0 0
Fatigue at initiation of treatment with pegcetacoplan and every 6 months until end of follow-up
Timepoint [66] 0 0
30 months
Secondary outcome [67] 0 0
Fatigue at initiation of treatment with pegcetacoplan and every 6 months until end of follow-up
Timepoint [67] 0 0
36 months
Secondary outcome [68] 0 0
Health care resource use: Annualized number of hospitalizations and emergency room visits during pegcetacoplan treatment until end of follow-up compared to the 12-month period before pegcetacoplan treatment.
Timepoint [68] 0 0
12 months
Secondary outcome [69] 0 0
Patient treatment satisfaction every 6 months until end of follow-up
Timepoint [69] 0 0
6 months
Secondary outcome [70] 0 0
Patient treatment satisfaction every 6 months until end of follow-up
Timepoint [70] 0 0
12 months
Secondary outcome [71] 0 0
Patient treatment satisfaction every 6 months until end of follow-up
Timepoint [71] 0 0
18 months
Secondary outcome [72] 0 0
Patient treatment satisfaction every 6 months until end of follow-up
Timepoint [72] 0 0
24 months
Secondary outcome [73] 0 0
Patient treatment satisfaction every 6 months until end of follow-up
Timepoint [73] 0 0
30 months
Secondary outcome [74] 0 0
Patient treatment satisfaction every 6 months until end of follow-up
Timepoint [74] 0 0
36 months
Secondary outcome [75] 0 0
Physician treatment satisfaction every 6 months until end of follow-up
Timepoint [75] 0 0
6 months
Secondary outcome [76] 0 0
Physician treatment satisfaction every 6 months until end of follow-up
Timepoint [76] 0 0
12 months
Secondary outcome [77] 0 0
Physician treatment satisfaction every 6 months until end of follow-up
Timepoint [77] 0 0
18 months
Secondary outcome [78] 0 0
Physician treatment satisfaction every 6 months until end of follow-up
Timepoint [78] 0 0
24 months
Secondary outcome [79] 0 0
Physician treatment satisfaction every 6 months until end of follow-up
Timepoint [79] 0 0
30 months
Secondary outcome [80] 0 0
Physician treatment satisfaction every 6 months until end of follow-up
Timepoint [80] 0 0
36 months
Secondary outcome [81] 0 0
Adverse events (AE), including serious adverse events (SAE)
Timepoint [81] 0 0
24 hours
Secondary outcome [82] 0 0
Alanine transaminase (ALT) at initiation of treatment with pegcetacoplan and every 6 months until end of follow-up
Timepoint [82] 0 0
6 months
Secondary outcome [83] 0 0
Alanine transaminase (ALT) at initiation of treatment with pegcetacoplan and every 6 months until end of follow-up
Timepoint [83] 0 0
12 months
Secondary outcome [84] 0 0
Alanine transaminase (ALT) at initiation of treatment with pegcetacoplan and every 6 months until end of follow-up
Timepoint [84] 0 0
18 months
Secondary outcome [85] 0 0
Alanine transaminase (ALT) at initiation of treatment with pegcetacoplan and every 6 months until end of follow-up
Timepoint [85] 0 0
24 months
Secondary outcome [86] 0 0
Alanine transaminase (ALT) at initiation of treatment with pegcetacoplan and every 6 months until end of follow-up
Timepoint [86] 0 0
30 months
Secondary outcome [87] 0 0
Alanine transaminase (ALT) at initiation of treatment with pegcetacoplan and every 6 months until end of follow-up
Timepoint [87] 0 0
36 months
Secondary outcome [88] 0 0
Aspartate aminotransferase (AST) at initiation of treatment with pegcetacoplan and every 6 months until end of follow-up
Timepoint [88] 0 0
6 months
Secondary outcome [89] 0 0
Aspartate aminotransferase (AST) at initiation of treatment with pegcetacoplan and every 6 months until end of follow-up
Timepoint [89] 0 0
12 months
Secondary outcome [90] 0 0
Aspartate aminotransferase (AST) at initiation of treatment with pegcetacoplan and every 6 months until end of follow-up
Timepoint [90] 0 0
18 months
Secondary outcome [91] 0 0
Aspartate aminotransferase (AST) at initiation of treatment with pegcetacoplan and every 6 months until end of follow-up
Timepoint [91] 0 0
24 months
Secondary outcome [92] 0 0
Aspartate aminotransferase (AST) at initiation of treatment with pegcetacoplan and every 6 months until end of follow-up
Timepoint [92] 0 0
30 months
Secondary outcome [93] 0 0
Aspartate aminotransferase (AST) at initiation of treatment with pegcetacoplan and every 6 months until end of follow-up
Timepoint [93] 0 0
36 months
Secondary outcome [94] 0 0
Alkaline Phosphatase at initiation of treatment with pegcetacoplan and every 6 months until end of follow-up
Timepoint [94] 0 0
6 months
Secondary outcome [95] 0 0
Alkaline Phosphatase at initiation of treatment with pegcetacoplan and every 6 months until end of follow-up
Timepoint [95] 0 0
12 months
Secondary outcome [96] 0 0
Alkaline Phosphatase at initiation of treatment with pegcetacoplan and every 6 months until end of follow-up
Timepoint [96] 0 0
18 months
Secondary outcome [97] 0 0
Alkaline Phosphatase at initiation of treatment with pegcetacoplan and every 6 months until end of follow-up
Timepoint [97] 0 0
24 months
Secondary outcome [98] 0 0
Alkaline Phosphatase at initiation of treatment with pegcetacoplan and every 6 months until end of follow-up
Timepoint [98] 0 0
30 months
Secondary outcome [99] 0 0
Alkaline Phosphatase at initiation of treatment with pegcetacoplan and every 6 months until end of follow-up
Timepoint [99] 0 0
36 months
Secondary outcome [100] 0 0
Bilirubin at initiation of treatment with pegcetacoplan and every 6 months until end of follow-up
Timepoint [100] 0 0
6 months
Secondary outcome [101] 0 0
Bilirubin at initiation of treatment with pegcetacoplan and every 6 months until end of follow-up
Timepoint [101] 0 0
12 months
Secondary outcome [102] 0 0
Bilirubin at initiation of treatment with pegcetacoplan and every 6 months until end of follow-up
Timepoint [102] 0 0
18 months
Secondary outcome [103] 0 0
Bilirubin at initiation of treatment with pegcetacoplan and every 6 months until end of follow-up
Timepoint [103] 0 0
24 months
Secondary outcome [104] 0 0
Bilirubin at initiation of treatment with pegcetacoplan and every 6 months until end of follow-up
Timepoint [104] 0 0
30 months
Secondary outcome [105] 0 0
Bilirubin at initiation of treatment with pegcetacoplan and every 6 months until end of follow-up
Timepoint [105] 0 0
36 months
Secondary outcome [106] 0 0
Creatinine at initiation of treatment with pegcetacoplan and every 6 months until end of follow-up
Timepoint [106] 0 0
6 months
Secondary outcome [107] 0 0
Creatinine at initiation of treatment with pegcetacoplan and every 6 months until end of follow-up
Timepoint [107] 0 0
12 months
Secondary outcome [108] 0 0
Creatinine at initiation of treatment with pegcetacoplan and every 6 months until end of follow-up
Timepoint [108] 0 0
18 months
Secondary outcome [109] 0 0
Creatinine at initiation of treatment with pegcetacoplan and every 6 months until end of follow-up
Timepoint [109] 0 0
24 months
Secondary outcome [110] 0 0
Creatinine at initiation of treatment with pegcetacoplan and every 6 months until end of follow-up
Timepoint [110] 0 0
30 months
Secondary outcome [111] 0 0
Creatinine at initiation of treatment with pegcetacoplan and every 6 months until end of follow-up
Timepoint [111] 0 0
36 months
Secondary outcome [112] 0 0
estimated glomerular filtration rate (eGFR) at initiation of treatment with pegcetacoplan and every 6 months until end of follow-up
Timepoint [112] 0 0
6 months
Secondary outcome [113] 0 0
estimated glomerular filtration rate (eGFR) at initiation of treatment with pegcetacoplan and every 6 months until end of follow-up
Timepoint [113] 0 0
12 months
Secondary outcome [114] 0 0
estimated glomerular filtration rate (eGFR) at initiation of treatment with pegcetacoplan and every 6 months until end of follow-up
Timepoint [114] 0 0
18 months
Secondary outcome [115] 0 0
estimated glomerular filtration rate (eGFR) at initiation of treatment with pegcetacoplan and every 6 months until end of follow-up
Timepoint [115] 0 0
24 months
Secondary outcome [116] 0 0
estimated glomerular filtration rate (eGFR) at initiation of treatment with pegcetacoplan and every 6 months until end of follow-up
Timepoint [116] 0 0
30 months
Secondary outcome [117] 0 0
estimated glomerular filtration rate (eGFR) at initiation of treatment with pegcetacoplan and every 6 months until end of follow-up
Timepoint [117] 0 0
36 months
Secondary outcome [118] 0 0
Urea at initiation of treatment with pegcetacoplan and every 6 months until end of follow-up
Timepoint [118] 0 0
6 months
Secondary outcome [119] 0 0
Urea at initiation of treatment with pegcetacoplan and every 6 months until end of follow-up
Timepoint [119] 0 0
12 months
Secondary outcome [120] 0 0
Urea at initiation of treatment with pegcetacoplan and every 6 months until end of follow-up
Timepoint [120] 0 0
18 months
Secondary outcome [121] 0 0
Urea at initiation of treatment with pegcetacoplan and every 6 months until end of follow-up
Timepoint [121] 0 0
24 months
Secondary outcome [122] 0 0
Urea at initiation of treatment with pegcetacoplan and every 6 months until end of follow-up
Timepoint [122] 0 0
30 months
Secondary outcome [123] 0 0
Urea at initiation of treatment with pegcetacoplan and every 6 months until end of follow-up
Timepoint [123] 0 0
36 months
Secondary outcome [124] 0 0
Potassium at initiation of treatment with pegcetacoplan and every 6 months until end of follow-up
Timepoint [124] 0 0
6 months
Secondary outcome [125] 0 0
Potassium at initiation of treatment with pegcetacoplan and every 6 months until end of follow-up
Timepoint [125] 0 0
12 months
Secondary outcome [126] 0 0
Potassium at initiation of treatment with pegcetacoplan and every 6 months until end of follow-up
Timepoint [126] 0 0
18 months
Secondary outcome [127] 0 0
Potassium at initiation of treatment with pegcetacoplan and every 6 months until end of follow-up
Timepoint [127] 0 0
24 months
Secondary outcome [128] 0 0
Potassium at initiation of treatment with pegcetacoplan and every 6 months until end of follow-up
Timepoint [128] 0 0
30 months
Secondary outcome [129] 0 0
Potassium at initiation of treatment with pegcetacoplan and every 6 months until end of follow-up
Timepoint [129] 0 0
36 months
Secondary outcome [130] 0 0
Sodium at initiation of treatment with pegcetacoplan and every 6 months until end of follow-up
Timepoint [130] 0 0
6 months
Secondary outcome [131] 0 0
Sodium at initiation of treatment with pegcetacoplan and every 6 months until end of follow-up
Timepoint [131] 0 0
12 months
Secondary outcome [132] 0 0
Sodium at initiation of treatment with pegcetacoplan and every 6 months until end of follow-up
Timepoint [132] 0 0
18 months
Secondary outcome [133] 0 0
Sodium at initiation of treatment with pegcetacoplan and every 6 months until end of follow-up
Timepoint [133] 0 0
24 months
Secondary outcome [134] 0 0
Sodium at initiation of treatment with pegcetacoplan and every 6 months until end of follow-up
Timepoint [134] 0 0
30 months
Secondary outcome [135] 0 0
Sodium at initiation of treatment with pegcetacoplan and every 6 months until end of follow-up
Timepoint [135] 0 0
36 months

Eligibility
Key inclusion criteria
* Patients =18 years of age with a documented PNH diagnosis.
* Patient started routine treatment with pegcetacoplan for PNH up to 12 months before enrollment or prescribed pegcetacoplan at enrollment. Decision to initiate treatment shall be made by the treating physician and independently from the decision to include the patient in the study.
* Patient is willing and able to provide written informed consent to participate in the study in a manner approved by the Institutional Review Board/Independent Ethics Committee and local regulations.
Minimum age
18 Years
Maximum age
No limit
Sex
Both males and females
Healthy volunteers
No
Key exclusion criteria
* Enrollment in a concurrent clinical interventional study, or intake of an Investigational Medicinal Product (IMP), within three months prior to the start of the current pegcetacoplan treatment.
* Initiated current treatment with pegcetacoplan in an interventional study.

Study design
Purpose
Duration
Selection
Timing
Statistical methods / analysis

Recruitment
Recruitment status
Active, not recruiting
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
Sample size
Target
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
NSW,QLD
Recruitment hospital [1] 0 0
Liverpool Hospital - Liverpool
Recruitment hospital [2] 0 0
Calvary Mater Newcastle - Waratah
Recruitment hospital [3] 0 0
Sunshine Coast University Hospital - Birtinya
Recruitment hospital [4] 0 0
Canberra Hospital - Garran
Recruitment postcode(s) [1] 0 0
- Liverpool
Recruitment postcode(s) [2] 0 0
- Waratah
Recruitment postcode(s) [3] 0 0
- Birtinya
Recruitment postcode(s) [4] 0 0
2605 - Garran
Recruitment outside Australia
Country [1] 0 0
Belgium
State/province [1] 0 0
Anderlecht
Country [2] 0 0
Belgium
State/province [2] 0 0
Bruges
Country [3] 0 0
Belgium
State/province [3] 0 0
Brussels
Country [4] 0 0
Belgium
State/province [4] 0 0
Liège
Country [5] 0 0
Belgium
State/province [5] 0 0
Turnhout
Country [6] 0 0
Canada
State/province [6] 0 0
Ontario
Country [7] 0 0
Canada
State/province [7] 0 0
Quebec
Country [8] 0 0
Croatia
State/province [8] 0 0
Zagreb
Country [9] 0 0
Czechia
State/province [9] 0 0
Brno
Country [10] 0 0
Czechia
State/province [10] 0 0
Prague
Country [11] 0 0
Finland
State/province [11] 0 0
Helsinki
Country [12] 0 0
France
State/province [12] 0 0
Alpes Maritimes
Country [13] 0 0
France
State/province [13] 0 0
Gironde
Country [14] 0 0
France
State/province [14] 0 0
Hauts de Seine
Country [15] 0 0
France
State/province [15] 0 0
Isere
Country [16] 0 0
France
State/province [16] 0 0
Loire Atlantique
Country [17] 0 0
France
State/province [17] 0 0
Meurthe et Moselle
Country [18] 0 0
France
State/province [18] 0 0
Nord
Country [19] 0 0
France
State/province [19] 0 0
Paris
Country [20] 0 0
France
State/province [20] 0 0
Rhone
Country [21] 0 0
France
State/province [21] 0 0
Poitiers
Country [22] 0 0
France
State/province [22] 0 0
Rennes
Country [23] 0 0
France
State/province [23] 0 0
Saint-Quentin
Country [24] 0 0
Germany
State/province [24] 0 0
Baden-Wurttemberg
Country [25] 0 0
Germany
State/province [25] 0 0
Bavaria
Country [26] 0 0
Germany
State/province [26] 0 0
Hesse
Country [27] 0 0
Germany
State/province [27] 0 0
North Rhine-Westphalia
Country [28] 0 0
Germany
State/province [28] 0 0
Saxony
Country [29] 0 0
Germany
State/province [29] 0 0
Thuringia
Country [30] 0 0
Germany
State/province [30] 0 0
Cologne
Country [31] 0 0
Germany
State/province [31] 0 0
Troisdorf
Country [32] 0 0
Greece
State/province [32] 0 0
Athens
Country [33] 0 0
Greece
State/province [33] 0 0
Larissa
Country [34] 0 0
Greece
State/province [34] 0 0
Thessaloniki
Country [35] 0 0
Hungary
State/province [35] 0 0
Budapest
Country [36] 0 0
Italy
State/province [36] 0 0
Bari
Country [37] 0 0
Italy
State/province [37] 0 0
Bassano del Grappa
Country [38] 0 0
Italy
State/province [38] 0 0
Bologna
Country [39] 0 0
Italy
State/province [39] 0 0
Cagliari
Country [40] 0 0
Italy
State/province [40] 0 0
Florence
Country [41] 0 0
Italy
State/province [41] 0 0
Milan
Country [42] 0 0
Italy
State/province [42] 0 0
Novara
Country [43] 0 0
Italy
State/province [43] 0 0
Reggio Calabria
Country [44] 0 0
Italy
State/province [44] 0 0
Roma
Country [45] 0 0
Italy
State/province [45] 0 0
Rome
Country [46] 0 0
Italy
State/province [46] 0 0
Torino
Country [47] 0 0
Poland
State/province [47] 0 0
Bialystok
Country [48] 0 0
Poland
State/province [48] 0 0
Bydgoszcz
Country [49] 0 0
Poland
State/province [49] 0 0
Gdansk
Country [50] 0 0
Poland
State/province [50] 0 0
Krakow
Country [51] 0 0
Poland
State/province [51] 0 0
Lodz
Country [52] 0 0
Poland
State/province [52] 0 0
Lublin
Country [53] 0 0
Poland
State/province [53] 0 0
Warsaw
Country [54] 0 0
Saudi Arabia
State/province [54] 0 0
Buraidah
Country [55] 0 0
Saudi Arabia
State/province [55] 0 0
Jeddah
Country [56] 0 0
Saudi Arabia
State/province [56] 0 0
Riyadh
Country [57] 0 0
Spain
State/province [57] 0 0
Badalona
Country [58] 0 0
Spain
State/province [58] 0 0
Barakaldo
Country [59] 0 0
Spain
State/province [59] 0 0
Barcelona
Country [60] 0 0
Spain
State/province [60] 0 0
Bilbao
Country [61] 0 0
Spain
State/province [61] 0 0
Donostia / San Sebastian
Country [62] 0 0
Spain
State/province [62] 0 0
El Palmar
Country [63] 0 0
Spain
State/province [63] 0 0
Huelva
Country [64] 0 0
Spain
State/province [64] 0 0
Las Palmas de Gran Canaria
Country [65] 0 0
Spain
State/province [65] 0 0
Lugo
Country [66] 0 0
Spain
State/province [66] 0 0
Málaga
Country [67] 0 0
Spain
State/province [67] 0 0
Oviedo
Country [68] 0 0
Spain
State/province [68] 0 0
Palma de Mallorca
Country [69] 0 0
Spain
State/province [69] 0 0
Santiago de Compostela
Country [70] 0 0
United Kingdom
State/province [70] 0 0
London

Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Name
Swedish Orphan Biovitrum
Address
Country
Secondary sponsor
Nil
Other collaborator category [1] 0 0
Commercial sector/industry
Name [1] 0 0
IQVIA Pty Ltd
Address [1] 0 0
Country [1] 0 0

Ethics approval
Ethics application status

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Clinical Program Lead +46 08-697-20 00
Address 0 0
Swedish Orphan Biovitrum
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Clinical Program Lead
Address 0 0
Country 0 0
Phone 0 0
+46 (0)8 697 20 00
Fax 0 0
Email 0 0
Contact person for scientific queries

Data sharing statement
Will individual participant data (IPD) for this trial be available (including data dictionaries)?
No
No/undecided IPD sharing reason/comment


What supporting documents are/will be available?

No Supporting Document Provided


Results publications and other study-related documents

No documents have been uploaded by study researchers.